Evidence map›Paper›PMID 34217414›Full record

ArticlePreventive medicine2021

Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond.

Jennifer M Croswell, Douglas A Corley, Jennifer Elston Lafata, Jennifer S Haas, John M Inadomi, Aruna Kamineni, Debra P Ritzwoller, Anil Vachani, Yingye Zheng, National Cancer Institute Population-based Research to Optimize the Screening Process (PROSPR) II Consortium

Abstract read
In one paragraph

Article in Preventive medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Trends in low-value cancer care during the COVID-19 pandemic.The American journal of managed care · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jennifer M CroswellDivision of Cancer Control and Population Sciences, National Cancer Institute, USA. Electronic address: croswellj@nih.gov.
Douglas A CorleyThe Permanente Medical Group, Kaiser Permanente, Northern California, USA.
Jennifer Elston LafataUniversity of North Carolina Lineberger Comprehensive Cancer Center and Eshelman School of Pharmacy, USA.
Jennifer S HaasDivision of General Internal Medicine, Massachusetts General Hospital, USA.
John M InadomiDepartment of Internal Medicine, University of Utah School of Medicine, USA.
Aruna KamineniKaiser Permanente Washington Health Research Institute, USA.
Debra P RitzwollerInstitute for Health Research, Kaiser Permanente Colorado, USA.
Anil VachaniDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, USA.
Yingye ZhengPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, USA.
National Cancer Institute Population-based Research to Optimize the Screening Process (PROSPR) II Consortium

Funding

PROSPR METRICS CISNET Collaboration Investigating Impact of Structural Racism/Discrimination on Cervical Screening Moonshot SupplementUM1CA221940 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHUBAK, JESSICA, HAAS, JENNIFER S · 2018 to 2023
$15.9M
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)UM1CA222035 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHUBAK, JESSICA, CORLEY, DOUGLAS ALLEN · 2018 to 2023
$15.6M
Center for Research to Optimize Precision Lung Cancer Screening in Diverse PopulationsUM1CA221939 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI RITZWOLLER, DEBRA P, VACHANI, ANIL · 2018 to 2023
$15.3M
Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24)U24CA221936 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ZHENG, YINGYE · 2018 to 2023
$5.7M
Intramural NIH HHS Z99 CA999999NCI NIH HHS U24 CA221936NCI NIH HHS UM1 CA221939NIH HHS U24CA221939
6 · The paper itself

Abstract

COVID-19 has proved enormously disruptive to the provision of cancer screening, which does not just represent an initial test but an entire process, including risk detection, diagnostic follow-up, and treatment. Successful delivery of services at all points in the process has been negatively affected by the pandemic. There is a void in empirical high-quality evidence to support a specific strategy for administering cancer screening during a pandemic and its resolution phase, but several pragmatic considerations can help guide prioritization efforts. Targeting guideline-eligible people who have never been screened, or those who are significantly out of date with screening, has the potential to maximize benefits now and into the future. Disruptions to care due to the pandemic could represent an unparalleled opportunity to reassess early detection programs towards an explicit, thoughtful, and just prioritization of populations historically experiencing cancer disparities. By focusing screening services on populations that have the most to gain, and by careful and deliberate planning for the period following the pandemic, we can positively affect cancer outcomes for all.

Indexed as

COVID-19NeoplasmsDelivery of Health CareEarly Detection of CancerHumansPandemicsSARS-CoV-2

Identifiers

PMID34217414
PMCPMC8722181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.